Neonatology Unit, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.
Dipartimento di Scienze della Vita e Sanità Pubblica, Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
JAMA Netw Open. 2024 Sep 3;7(9):e2435347. doi: 10.1001/jamanetworkopen.2024.35347.
A multicenter randomized clinical trial (RCT) showed a lung recruitment maneuver using high-frequency oscillatory ventilation just before surfactant administration (ie, intubate-recruit-surfactant-extubate [IN-REC-SUR-E]) improved the efficacy of treatment compared with the standard intubate-surfactant-extubate (IN-SUR-E) technique without increasing the risk of adverse neonatal outcomes.
To examine follow-up outcomes at corrected postnatal age (cPNA) 2 years of preterm infants previously enrolled in an RCT and treated with IN-REC-SUR-E or IN-SUR-E in 35 tertiary neonatal intensive care units.
DESIGN, SETTING, AND PARTICIPANTS: This was a follow-up study of infants recruited into the primary RCT from 2015 to 2018 at 35 tertiary neonatal intensive care units (NICUs) in Italy. Follow-up examinations included neurodevelopmental, growth, and respiratory outcomes of these children at cPNA 2 years. Participants included spontaneously breathing extremely preterm neonates (24 0/7 to 27 6/7 weeks' gestation) reaching failure criteria for continuous positive airway pressure within the first 24 hours of life. Data were analyzed from April 2023 to January 2024.
Infants were randomly assigned (1:1) to IN-REC-SUR-E or IN-SUR-E and then followed up.
The primary outcome was the occurrence of death after discharge or major disability at cPNA 2 years. Secondary outcomes were neurodevelopmental outcomes (major disability, cerebral palsy, cognitive impairment, visual deficit, or auditory deficit), anthropometric measurements (weight, length, and head circumference), and recurrent respiratory infections and hospitalizations because of respiratory causes at 2y cPNA.
A total of 137 extremely preterm infants (median [IQR] gestational age, 26.5 [25.3-27.5] weeks and 75 [54.7%] female), initially enrolled in the original RCT, were followed up at cPNA 2 years, including 64 infants in the IN-SUR-E group and 73 infants in the IN-REC-SUR-E group. There were no significant differences in the occurrence of death after discharge or major disability at cPNA 2 years (IN-SUR-E: 13 children [20.3%] vs IN-REC-SUR-E: 10 children [13.7%]; P = .36). There were no significant differences in incidence of disability, cerebral palsy, or cognitive impairment in the IN-REC-SUR-E group compared with the IN-SUR-E group. There were no significant differences in anthropometric measurements (weight, length, and head circumference) between groups. There were no significant differences in the incidence of recurrent respiratory infections or in hospitalizations because of respiratory causes between groups.
In this RCT of lung recruitment before surfactant vs standard care there were no significant differences between the 2 groups in death, neurodevelopmental outcomes, anthropometric measurements, or recurrent respiratory infections at the 2-year follow-up. These findings can aid clinicians in decision-making for the best strategy to administer surfactant, considering long-term outcomes.
一项多中心随机临床试验(RCT)表明,在表面活性剂给药前使用高频振荡通气进行肺复张(即插管-复张-表面活性剂-拔管 [IN-REC-SUR-E])与标准插管-表面活性剂-拔管(IN-SUR-E)技术相比,可提高治疗效果,而不会增加不良新生儿结局的风险。
在意大利 35 家三级新生儿重症监护病房(NICU)中,对先前参加 IN-REC-SUR-E 或 IN-SUR-E 治疗的接受 RCT 治疗的早产儿,在矫正胎龄(cPNA) 2 岁时进行随访评估。
设计、地点和参与者:这是对 2015 年至 2018 年期间在意大利 35 家三级 NICU 中参加主要 RCT 的婴儿进行的随访研究。随访检查包括这些儿童在 cPNA 2 岁时的神经发育、生长和呼吸结局。参与者包括在生命的头 24 小时内达到持续气道正压通气失败标准的自发性呼吸极早产儿(24 0/7 至 27 6/7 周)。数据于 2023 年 4 月至 2024 年 1 月进行分析。
婴儿被随机分配(1:1)接受 IN-REC-SUR-E 或 IN-SUR-E 治疗,然后进行随访。
主要结局是出院后或 cPNA 2 岁时发生死亡或主要残疾。次要结局是神经发育结局(主要残疾、脑瘫、认知障碍、视力缺陷或听力缺陷)、人体测量测量(体重、长度和头围)以及因呼吸原因在 cPNA 2 岁时再次发生呼吸感染和住院的情况。
共有 137 名极早产儿(中位数 [IQR] 胎龄,26.5 [25.3-27.5] 周和 75 [54.7%] 名女性),最初参加了原始 RCT,在 cPNA 2 岁时进行了随访,其中 IN-SUR-E 组有 64 名婴儿,IN-REC-SUR-E 组有 73 名婴儿。出院后或 cPNA 2 岁时发生死亡或主要残疾的比例在两组间无显著差异(IN-SUR-E:13 例儿童 [20.3%] vs IN-REC-SUR-E:10 例儿童 [13.7%];P = .36)。与 IN-SUR-E 组相比,IN-REC-SUR-E 组残疾、脑瘫或认知障碍的发生率无显著差异。两组间体重、长度和头围的人体测量测量无显著差异。两组间因呼吸原因再次发生呼吸感染或住院的发生率无显著差异。
在这项关于肺复张与标准护理相比表面活性剂的 RCT 中,两组在 2 年随访时的死亡、神经发育结局、人体测量测量或反复呼吸道感染方面无显著差异。这些发现可以帮助临床医生在考虑长期结局时,为表面活性剂的最佳给药策略做出决策。